Tanaka Growth holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Tanaka Growth Fund TGFRX
- NAV / 1-Day Return 65.61 / −0.85 %
- Total Assets 39.2M
-
Adj. Expense Ratio
1.950%
- Expense Ratio 1.950%
- Distribution Fee Level High
- Share Class Type No Load
- Category Large Growth
- Investment Style Mid Growth
- Min. Initial Investment 2,000
- Status Open
- TTM Yield 0.00
- Turnover 23%
USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:11 AM GMT+0
Morningstar’s Analysis TGFRX
Will TGFRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 55.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Cash & Cash Equivalents | 14.08 | 5M | Cash and Equivalents |
United States Antimony Corp | 7.83 | 3M | Basic Materials |
Nuvation Bio Inc Ordinary Shares - Class A | 7.73 | 3M | Healthcare |
NVIDIA Corp | 6.66 | 2M | Technology |
NexGen Energy Ltd | 6.57 | 2M | Energy |
Aura Minerals Inc | 6.43 | 2M | Basic Materials |
Corcept Therapeutics Inc | 5.03 | 2M | Healthcare |
Apple Inc | 4.67 | 2M | Technology |
Applied Materials Inc | 3.88 | 1M | Technology |
Intellia Therapeutics Inc | 3.71 | 1M | Healthcare |